Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/11/21 EDT
87.05quote price arrow up+1.05 (+1.22%)
Volume
29,578
Close
86.00quote price arrow down-0.75 (-0.86%)
Volume
1,096,050
52 week range
67.68 - 181.83

...

Loading . . .
  • Open86.00
  • Day High86.78
  • Day Low84.75
  • Prev Close86.75
  • 52 Week High181.83
  • 52 Week High Date12/22/20
  • 52 Week Low67.68
  • 52 Week Low Date05/11/21

Key Stats

  • Market Cap6.86B
  • Shares Out79.77M
  • 10 Day Average Volume1.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.43
  • YTD % Change-49.56

KEY STATS

  • Open86.00
  • Day High86.78
  • Day Low84.75
  • Prev Close86.75
  • 52 Week High181.83
  • 52 Week High Date12/22/20
  • 52 Week Low67.68
  • 52 Week Low Date05/11/21
  • Market Cap6.86B
  • Shares Out79.77M
  • 10 Day Average Volume1.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.43
  • YTD % Change-49.56

RATIOS/PROFITABILITY

  • EPS (TTM)-8.94
  • P/E (TTM)-9.62
  • Fwd P/E (NTM)-13.36
  • EBITDA (MRQ)-558.69M
  • ROE (MRQ)-83.78%
  • Revenue (MRQ)573.36M
  • Gross Margin (MRQ)87.25%
  • Net Margin (MRQ)-122.77%
  • Debt To Equity (MRQ)203.78%

EVENTS

  • Earnings Date08/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its...
M. Kathleen Behrens Ph.D.
Non-Executive Chairman
Douglas Ingram Esq., J.D.
President
Ian Estepan
Chief Financial Officer
Louise Rodino-Klapac Ph.D.
Executive Vice President
William Ciambrone
Executive Vice President
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
GLPG
Galapagos NV
79.34-1.33-1.65%
HALO
Halozyme Therapeutics Inc
42.79+1.07+2.56%
RARE
Ultragenyx Pharmaceutical Inc
101.71+2.35+2.37%
NVTA
Invitae Corp
31.22-0.07-0.22%
ACAD
ACADIA Pharmaceuticals Inc
27.42+0.12+0.44%